PDS Biotechnology Corp 8K

PDS Biotechnology is discontinuing internal funding of its PDS0101 Phase 3 trial to refocus resources on PDS0301 and seek partnerships for PDS0101 following a strategic portfolio and capital review.

On August 11, 2026, PDS Biotechnology Corporation announced a strategic refocus of its development and capital allocation priorities, deciding to prioritize and advance its tumor-targeted IL-12 immunocytokine PDS0301—particularly in metastatic microsatellite stable/mismatch repair-proficient colorectal cancer via a randomized Phase 2b program—while ceasing further internal investment and discontinuing the Phase 3 VERSATILE-003 trial of its HPV16-targeted candidate PDS0101 and instead seeking strategic partnerships or other externally funded arrangements to continue PDS0101’s development; management emphasized this shift is driven by encouraging Phase 2 data for PDS0301, perceived broader combination-therapy potential across multiple difficult-to-treat solid tumors, and a desire for more disciplined capital deployment to maximize long-term shareholder value, and also noted that second-quarter 2026 financial results will be reported on August 13, 2026.

Filing Facts

CIK

1472091

Ticker

-

Form

8K

Source Type

sec

Accession

0001140361-26-032142

Alert Tier

7